search
Back to results

Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand

Primary Purpose

Osteoarthritis Hand

Status
Not yet recruiting
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
local anaesthetic injection
Human Adipose Allograft
Sponsored by
Cedars-Sinai Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis Hand

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Patients greater than 18 years, with presentation to the Cedars Sinai hand clinic for joint pain of the hand carpometacarpal, interphalangeal, proximal interphalangeal, and distal interphalangeal joints (CMC, IP, PIP or DIP joints). Radiographic evidence of osteoarthritis. Exclusion Criteria: Prior intervention for the presenting joint (either in the form of cortisone or hyaluronic acid injection or surgery). Rheumatoid or other inflammatory arthritis condition Collagen vascular disease Pregnancy or breast-feeding Congestive heart failure Chronic obstructive pulmonary disease Chronic renal failure Those who had medication or oral supplements for the previous 4 weeks that could prolong bleeding time (e.g.; Aspirin, Plavix).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    Adipose Allograft Matrix (AAM)

    Arm Description

    Using fluoroscopic guidance (X-ray), a needle will be injected into the joint space. 1 cc of Leneva (adipose allograft matrix, MTF Biologics) will be injected into the joint.

    Outcomes

    Primary Outcome Measures

    Range of Motion
    Measured with a standardized goniometer
    Range of Motion
    Measured with a standardized goniometer
    Range of Motion
    Measured with a standardized goniometer
    Range of Motion
    Measured with a standardized goniometer
    Strength Measures
    Strength to grip, key pinch and tip pinch, as measured by Jamar dynamometer device)
    Strength Measures
    Strength to grip, key pinch and tip pinch (as measured by Jamar dynamometer device)
    Strength Measures
    Strength to grip, key pinch and tip pinch (as measured by Jamar dynamometer device)
    Strength Measures
    Strength to grip, key pinch and tip pinch (as measured by Jamar dynamometer device)
    Pain scale scores
    Measured using the visual analogue scale (VAS) scored 0 (no pain=better outcome) to 10 (worst pain=worse outcome)
    Pain scale scores
    Measured using the visual analogue scale (VAS) scored 0 (no pain=better outcome) to 10 (worst pain=worse outcome)
    Pain scale scores
    Measured using the visual analogue scale (VAS) scored 0 (no pain=better outcome) to 10 (worst pain=worse outcome)
    Pain scale scores
    Measured using the visual analogue scale (VAS) scored 0 (no pain=better outcome) to 10 (worst pain=worse outcome)
    Disability Measurement
    DASH (Disability of the Arm, Shoulder and Hand) score The DASH is a 30-item self-reported questionnaire in which the response options are presented as 5-point Likert scales. Scores range from 0 (no disability) to 100 (most severe disability). This score was designed be useful in patients with any musculoskeletal disorder of the upper limb.
    Disability Measurement
    DASH (Disability of the Arm, Shoulder and Hand) score The DASH is a 30-item self-reported questionnaire in which the response options are presented as 5-point Likert scales. Scores range from 0 (no disability) to 100 (most severe disability). This score was designed be useful in patients with any musculoskeletal disorder of the upper limb.
    Disability Measurement
    DASH (Disability of the Arm, Shoulder and Hand) score The DASH is a 30-item self-reported questionnaire in which the response options are presented as 5-point Likert scales. Scores range from 0 (no disability) to 100 (most severe disability). This score was designed be useful in patients with any musculoskeletal disorder of the upper limb.
    Disability Measurement
    DASH (Disability of the Arm, Shoulder and Hand) score The DASH is a 30-item self-reported questionnaire in which the response options are presented as 5-point Likert scales. Scores range from 0 (no disability) to 100 (most severe disability). This score was designed be useful in patients with any musculoskeletal disorder of the upper limb.
    Patient satisfaction
    Five-point Likert scale (from 1 "strong disagree" to 5 "strongly agree") for the following two survey points: Satisfaction of patient with the procedure and would the patient recommend this procedure to others.
    Patient satisfaction
    Five-point Likert scale (from 1 "strong disagree" to 5 "strongly agree") " for the following two survey points: Satisfaction of patient with the procedure and would the patient recommend this procedure to others.
    Patient satisfaction
    Five-point Likert scale (from 1 "strong disagree" to 5 "strongly agree") for the following two survey points: Satisfaction of patient with the procedure and would the patient recommend this procedure to others.
    Patient satisfaction
    Five-point Likert scale (from 1 "strong disagree" to 5 "strongly agree") for the following two survey points: Satisfaction of patient with the procedure and would the patient recommend this procedure to others.

    Secondary Outcome Measures

    Incidence of Adverse Events
    Recording of adverse events

    Full Information

    First Posted
    February 5, 2023
    Last Updated
    March 6, 2023
    Sponsor
    Cedars-Sinai Medical Center
    Collaborators
    Musculoskeletal Transplant Foundation
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05747469
    Brief Title
    Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand
    Official Title
    Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    March 2023 (Anticipated)
    Primary Completion Date
    January 2024 (Anticipated)
    Study Completion Date
    January 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Cedars-Sinai Medical Center
    Collaborators
    Musculoskeletal Transplant Foundation

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No

    5. Study Description

    Brief Summary
    The purpose the research is to evaluate the safety and efficacy of injection of adipose allograft matrix (AAM) to the small joints of the hand for treatment of early stage osteoarthritis. The hypothesis is that use of AAM injected directly into the joint will show improvements in pain and disability while providing a safe, off-the-shelf alternative which can obviate the need for, and risks associated with, current treatment options with autologous fat transfer. As standard of care, routine strength, pain scale scores (VAS) and range of motion will be recorded, a baseline disability survey (DASH score) will also be administered. After these have all been recorded and administered in a separate visit the patient will undergo the lipofilling procedure. The subject population will include patients over the age of 18 who present with joint pain of the hand with radiographic evidence of osteoarthritis.
    Detailed Description
    The investigators central hypothesis is that use of AAM injected directly into the joint will show improvements in pain and disability while providing a safe, off-the-shelf alternative which can obviate the need for, and risks associated with, current treatment options. The overall aim of the project is to validate the clinical use of AAM for the treatment of early-stage osteoarthritis of the hand in adult patients (>18 years of age). The specific aims for this project are: To determine the safety of use of Leneva as a lipofilling alternative to autologous fat grafting for arthritis of the hand a. To determine safety, the investigators will evaluate for any adverse reactions to the injection at each of the follow up time-points To determine the efficacy of the technique as measured by clinical outcomes in terms of pain, disability, range of motion and strength a. To determine efficacy, the investigators will measure visual analogue pain scale scores as measures by visual analogue scale, disability scores as measured with DASH scores, and standardized range of motion and strengths scores as measured by the same study administrator at each of the follow up time points To determine patient satisfaction with the procedure a. To determine patient satisfaction, the investigators will administer a survey at each of the follow up time points

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Osteoarthritis Hand

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Early Phase 1
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    20 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Adipose Allograft Matrix (AAM)
    Arm Type
    Other
    Arm Description
    Using fluoroscopic guidance (X-ray), a needle will be injected into the joint space. 1 cc of Leneva (adipose allograft matrix, MTF Biologics) will be injected into the joint.
    Intervention Type
    Drug
    Intervention Name(s)
    local anaesthetic injection
    Other Intervention Name(s)
    Lidocaine
    Intervention Description
    Subcutaneous local anesthesia with 1% lidocaine without epinephrine is administered to the skin overlying the joint.
    Intervention Type
    Procedure
    Intervention Name(s)
    Human Adipose Allograft
    Other Intervention Name(s)
    Leneva
    Intervention Description
    Light axial traction of the digit is used to open the joint space when introducing the 18-gauge needle. Fluoroscopy is used to assist with visualization 1 cc of Leneva is injected into the CMC joint and 0.5 cc in the IP, PIP and DIP joints. The puncture is dressed with a band-aid and coban wrap, which will be worn for 48 hours. Return to work and normal use of the hand is recommended at 48 hours. No narcotics are prescribed.
    Primary Outcome Measure Information:
    Title
    Range of Motion
    Description
    Measured with a standardized goniometer
    Time Frame
    Pre-procedure
    Title
    Range of Motion
    Description
    Measured with a standardized goniometer
    Time Frame
    6 weeks
    Title
    Range of Motion
    Description
    Measured with a standardized goniometer
    Time Frame
    6 month
    Title
    Range of Motion
    Description
    Measured with a standardized goniometer
    Time Frame
    12 months
    Title
    Strength Measures
    Description
    Strength to grip, key pinch and tip pinch, as measured by Jamar dynamometer device)
    Time Frame
    Pre-procedure
    Title
    Strength Measures
    Description
    Strength to grip, key pinch and tip pinch (as measured by Jamar dynamometer device)
    Time Frame
    6 weeks
    Title
    Strength Measures
    Description
    Strength to grip, key pinch and tip pinch (as measured by Jamar dynamometer device)
    Time Frame
    6 months
    Title
    Strength Measures
    Description
    Strength to grip, key pinch and tip pinch (as measured by Jamar dynamometer device)
    Time Frame
    12 months
    Title
    Pain scale scores
    Description
    Measured using the visual analogue scale (VAS) scored 0 (no pain=better outcome) to 10 (worst pain=worse outcome)
    Time Frame
    Pre-procedure
    Title
    Pain scale scores
    Description
    Measured using the visual analogue scale (VAS) scored 0 (no pain=better outcome) to 10 (worst pain=worse outcome)
    Time Frame
    6 weeks
    Title
    Pain scale scores
    Description
    Measured using the visual analogue scale (VAS) scored 0 (no pain=better outcome) to 10 (worst pain=worse outcome)
    Time Frame
    6 months
    Title
    Pain scale scores
    Description
    Measured using the visual analogue scale (VAS) scored 0 (no pain=better outcome) to 10 (worst pain=worse outcome)
    Time Frame
    12 months
    Title
    Disability Measurement
    Description
    DASH (Disability of the Arm, Shoulder and Hand) score The DASH is a 30-item self-reported questionnaire in which the response options are presented as 5-point Likert scales. Scores range from 0 (no disability) to 100 (most severe disability). This score was designed be useful in patients with any musculoskeletal disorder of the upper limb.
    Time Frame
    Pre-procedure
    Title
    Disability Measurement
    Description
    DASH (Disability of the Arm, Shoulder and Hand) score The DASH is a 30-item self-reported questionnaire in which the response options are presented as 5-point Likert scales. Scores range from 0 (no disability) to 100 (most severe disability). This score was designed be useful in patients with any musculoskeletal disorder of the upper limb.
    Time Frame
    6 weeks
    Title
    Disability Measurement
    Description
    DASH (Disability of the Arm, Shoulder and Hand) score The DASH is a 30-item self-reported questionnaire in which the response options are presented as 5-point Likert scales. Scores range from 0 (no disability) to 100 (most severe disability). This score was designed be useful in patients with any musculoskeletal disorder of the upper limb.
    Time Frame
    6 months
    Title
    Disability Measurement
    Description
    DASH (Disability of the Arm, Shoulder and Hand) score The DASH is a 30-item self-reported questionnaire in which the response options are presented as 5-point Likert scales. Scores range from 0 (no disability) to 100 (most severe disability). This score was designed be useful in patients with any musculoskeletal disorder of the upper limb.
    Time Frame
    12 months
    Title
    Patient satisfaction
    Description
    Five-point Likert scale (from 1 "strong disagree" to 5 "strongly agree") for the following two survey points: Satisfaction of patient with the procedure and would the patient recommend this procedure to others.
    Time Frame
    Day of procedure
    Title
    Patient satisfaction
    Description
    Five-point Likert scale (from 1 "strong disagree" to 5 "strongly agree") " for the following two survey points: Satisfaction of patient with the procedure and would the patient recommend this procedure to others.
    Time Frame
    6 weeks
    Title
    Patient satisfaction
    Description
    Five-point Likert scale (from 1 "strong disagree" to 5 "strongly agree") for the following two survey points: Satisfaction of patient with the procedure and would the patient recommend this procedure to others.
    Time Frame
    6 months
    Title
    Patient satisfaction
    Description
    Five-point Likert scale (from 1 "strong disagree" to 5 "strongly agree") for the following two survey points: Satisfaction of patient with the procedure and would the patient recommend this procedure to others.
    Time Frame
    12 months
    Secondary Outcome Measure Information:
    Title
    Incidence of Adverse Events
    Description
    Recording of adverse events
    Time Frame
    0-12 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patients greater than 18 years, with presentation to the Cedars Sinai hand clinic for joint pain of the hand carpometacarpal, interphalangeal, proximal interphalangeal, and distal interphalangeal joints (CMC, IP, PIP or DIP joints). Radiographic evidence of osteoarthritis. Exclusion Criteria: Prior intervention for the presenting joint (either in the form of cortisone or hyaluronic acid injection or surgery). Rheumatoid or other inflammatory arthritis condition Collagen vascular disease Pregnancy or breast-feeding Congestive heart failure Chronic obstructive pulmonary disease Chronic renal failure Those who had medication or oral supplements for the previous 4 weeks that could prolong bleeding time (e.g.; Aspirin, Plavix).
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Joel C Program Manager
    Phone
    (310) 423-4614
    Email
    joel.arnold@cshs.org
    First Name & Middle Initial & Last Name or Official Title & Degree
    Laura Program Manager
    Phone
    (310) 423-4295
    Email
    laura.sarmeinto@cshs.org
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Meghan McCullough, MD
    Organizational Affiliation
    Cedars-Sinai Medical Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    18261664
    Citation
    Heyworth BE, Lee JH, Kim PD, Lipton CB, Strauch RJ, Rosenwasser MP. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am. 2008 Jan;33(1):40-8. doi: 10.1016/j.jhsa.2007.10.009.
    Results Reference
    background
    PubMed Identifier
    31592943
    Citation
    Haas EM, Eisele A, Arnoldi A, Paolini M, Ehrl D, Volkmer E, Giunta RE. One-Year Outcomes of Intraarticular Fat Transplantation for Thumb Carpometacarpal Joint Osteoarthritis: Case Review of 99 Joints. Plast Reconstr Surg. 2020 Jan;145(1):151-159. doi: 10.1097/PRS.0000000000006378.
    Results Reference
    background
    PubMed Identifier
    22787504
    Citation
    Holland C, Jaeger L, Smentkowski U, Weber B, Otto C. Septic and aseptic complications of corticosteroid injections: an assessment of 278 cases reviewed by expert commissions and mediation boards from 2005 to 2009. Dtsch Arztebl Int. 2012 Jun;109(24):425-30. doi: 10.3238/arztebl.2012.0425. Epub 2012 Jun 15.
    Results Reference
    background
    PubMed Identifier
    21222099
    Citation
    McGarry JG, Daruwalla ZJ. The efficacy, accuracy and complications of corticosteroid injections of the knee joint. Knee Surg Sports Traumatol Arthrosc. 2011 Oct;19(10):1649-54. doi: 10.1007/s00167-010-1380-1. Epub 2011 Jan 11.
    Results Reference
    background
    PubMed Identifier
    5409431
    Citation
    Buck-Gramcko D. [Denervation of the wrist joint and interphalageal joints]. Handchirurgie. 1969;1(4):179-81. No abstract available. German.
    Results Reference
    background
    PubMed Identifier
    7468170
    Citation
    Lucht U, Vang PS, Munck J. Soft tissue interposition arthroplasty for osteoarthritis of the carpometacarpal joint of the thumb. Acta Orthop Scand. 1980 Oct;51(5):767-71. doi: 10.3109/17453678008990872.
    Results Reference
    background
    PubMed Identifier
    14508641
    Citation
    Deb R, Sauerbier M, Rauschmann MA. [History of arthroplasty for finger joints]. Orthopade. 2003 Sep;32(9):770-8. doi: 10.1007/s00132-003-0518-y. German.
    Results Reference
    background
    PubMed Identifier
    18972098
    Citation
    Bruser P. [Modified volar plate arthroplasty for posttraumatic and idiopathic osteoarthritis of the metacarpophalangeal and proximal interphalangeal joints]. Orthopade. 2008 Dec;37(12):1180-6. doi: 10.1007/s00132-008-1324-3. German.
    Results Reference
    background
    PubMed Identifier
    5055148
    Citation
    Swanson AB. Disabling arthritis at the base of the thumb: treatment by resection of the trapezium and flexible (silicone) implant arthroplasty. J Bone Joint Surg Am. 1972 Apr;54(3):456-71. No abstract available.
    Results Reference
    background
    PubMed Identifier
    5055146
    Citation
    Swanson AB. Flexible implant arthroplasty for arthritic finger joints: rationale, technique, and results of treatment. J Bone Joint Surg Am. 1972 Apr;54(3):435-55. No abstract available.
    Results Reference
    background
    PubMed Identifier
    17187336
    Citation
    Heers G, Grifka J, Borisch N. [First results after implantation of a pyrocarbon-endoprosthesis in patients with degenerative arthritis]. Z Orthop Ihre Grenzgeb. 2006 Nov-Dec;144(6):609-13. doi: 10.1055/s-2006-955189. German.
    Results Reference
    background
    PubMed Identifier
    1401814
    Citation
    IJsselstein CB, van Egmond DB, Hovius SE, van der Meulen JC. Results of small-joint arthrodesis: comparison of Kirschner wire fixation with tension band wire technique. J Hand Surg Am. 1992 Sep;17(5):952-6. doi: 10.1016/0363-5023(92)90476-6.
    Results Reference
    background
    PubMed Identifier
    28369017
    Citation
    Herold C, Rennekampff HO, Groddeck R, Allert S. Autologous Fat Transfer for Thumb Carpometacarpal Joint Osteoarthritis: A Prospective Study. Plast Reconstr Surg. 2017 Aug;140(2):327-335. doi: 10.1097/PRS.0000000000003510.
    Results Reference
    background
    PubMed Identifier
    29966351
    Citation
    Damia E, Chicharro D, Lopez S, Cuervo B, Rubio M, Sopena JJ, Vilar JM, Carrillo JM. Adipose-Derived Mesenchymal Stem Cells: Are They a Good Therapeutic Strategy for Osteoarthritis? Int J Mol Sci. 2018 Jun 30;19(7):1926. doi: 10.3390/ijms19071926.
    Results Reference
    background
    PubMed Identifier
    19003780
    Citation
    Black LL, Gaynor J, Adams C, Dhupa S, Sams AE, Taylor R, Harman S, Gingerich DA, Harman R. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 2008 Fall;9(3):192-200.
    Results Reference
    background
    PubMed Identifier
    22961401
    Citation
    ter Huurne M, Schelbergen R, Blattes R, Blom A, de Munter W, Grevers LC, Jeanson J, Noel D, Casteilla L, Jorgensen C, van den Berg W, van Lent PL. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. Arthritis Rheum. 2012 Nov;64(11):3604-13. doi: 10.1002/art.34626.
    Results Reference
    background
    PubMed Identifier
    28560007
    Citation
    Zhang L, Wang XY, Zhou PJ, He Z, Yan HZ, Xu DD, Wang Y, Fu WY, Ruan BB, Wang S, Chen HX, Liu QY, Zhang YX, Liu Z, Wang YF. Use of immune modulation by human adipose-derived mesenchymal stem cells to treat experimental arthritis in mice. Am J Transl Res. 2017 May 15;9(5):2595-2607. eCollection 2017.
    Results Reference
    background
    PubMed Identifier
    23042088
    Citation
    Wu L, Cai X, Zhang S, Karperien M, Lin Y. Regeneration of articular cartilage by adipose tissue derived mesenchymal stem cells: perspectives from stem cell biology and molecular medicine. J Cell Physiol. 2013 May;228(5):938-44. doi: 10.1002/jcp.24255.
    Results Reference
    background
    PubMed Identifier
    28986619
    Citation
    Chiari C, Walzer S, Stelzeneder D, Schreiner M, Windhager R. [Therapeutic utilization of stem cells in orthopedics]. Orthopade. 2017 Dec;46(12):1077-1090. doi: 10.1007/s00132-017-3475-6. Erratum In: Orthopade. 2018 Jan 5;: German.
    Results Reference
    background
    PubMed Identifier
    26333991
    Citation
    Banyard DA, Borad V, Amezcua E, Wirth GA, Evans GR, Widgerow AD. Preparation, Characterization, and Clinical Implications of Human Decellularized Adipose Tissue Extracellular Matrix (hDAM): A Comprehensive Review. Aesthet Surg J. 2016 Mar;36(3):349-57. doi: 10.1093/asj/sjv170. Epub 2015 Sep 1.
    Results Reference
    background
    PubMed Identifier
    24035153
    Citation
    Sano H, Orbay H, Terashi H, Hyakusoku H, Ogawa R. Acellular adipose matrix as a natural scaffold for tissue engineering. J Plast Reconstr Aesthet Surg. 2014 Jan;67(1):99-106. doi: 10.1016/j.bjps.2013.08.006. Epub 2013 Sep 12.
    Results Reference
    background
    PubMed Identifier
    26360790
    Citation
    Han TT, Toutounji S, Amsden BG, Flynn LE. Adipose-derived stromal cells mediate in vivo adipogenesis, angiogenesis and inflammation in decellularized adipose tissue bioscaffolds. Biomaterials. 2015 Dec;72:125-37. doi: 10.1016/j.biomaterials.2015.08.053. Epub 2015 Aug 31.
    Results Reference
    background
    PubMed Identifier
    24510423
    Citation
    Adam Young D, Bajaj V, Christman KL. Award winner for outstanding research in the PhD category, 2014 Society for Biomaterials annual meeting and exposition, Denver, Colorado, April 16-19, 2014: Decellularized adipose matrix hydrogels stimulate in vivo neovascularization and adipose formation. J Biomed Mater Res A. 2014 Jun;102(6):1641-51. doi: 10.1002/jbm.a.35109. Epub 2014 Feb 24.
    Results Reference
    background
    PubMed Identifier
    32095393
    Citation
    Kokai LE, Sivak WN, Schilling BK, Karunamurthy A, Egro FM, Schusterman MA, Minteer DM, Simon P, D'Amico RA, Rubin JP. Clinical Evaluation of an Off-the-Shelf Allogeneic Adipose Matrix for Soft Tissue Reconstruction. Plast Reconstr Surg Glob Open. 2020 Jan 27;8(1):e2574. doi: 10.1097/GOX.0000000000002574. eCollection 2020 Jan.
    Results Reference
    background
    PubMed Identifier
    20304481
    Citation
    Flynn LE. The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells. Biomaterials. 2010 Jun;31(17):4715-24. doi: 10.1016/j.biomaterials.2010.02.046. Epub 2010 Mar 20.
    Results Reference
    background
    PubMed Identifier
    21448993
    Citation
    Choi JS, Kim BS, Kim JY, Kim JD, Choi YC, Yang HJ, Park K, Lee HY, Cho YW. Decellularized extracellular matrix derived from human adipose tissue as a potential scaffold for allograft tissue engineering. J Biomed Mater Res A. 2011 Jun 1;97(3):292-9. doi: 10.1002/jbm.a.33056. Epub 2011 Mar 29.
    Results Reference
    background
    PubMed Identifier
    21043998
    Citation
    Brown BN, Freund JM, Han L, Rubin JP, Reing JE, Jeffries EM, Wolf MT, Tottey S, Barnes CA, Ratner BD, Badylak SF. Comparison of three methods for the derivation of a biologic scaffold composed of adipose tissue extracellular matrix. Tissue Eng Part C Methods. 2011 Apr;17(4):411-21. doi: 10.1089/ten.TEC.2010.0342. Epub 2011 Feb 5.
    Results Reference
    background

    Learn more about this trial

    Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand

    We'll reach out to this number within 24 hrs